ABSTRACT
This chapter presents classification & mode of action, indications & dermatological uses, formulations/presentation, dosages & suggested regimens, baseline investigations, considerations & monitoring, contraindications, cautions, important drug interactions, adverse effects & their management, use in special situations, and essential patient information of Antimalarials. Antimalarials are the first choice oral therapy for all patients with cutaneous lupus erythematosus, as well as the majority with systemic forms of the disease. The mode of action of antimalarials in dermatological disease is uncertain, although research has led to a clearer understanding of their mode of action. In addition to cutaneous lupus, other evidence-based dermatological indications for antimalarials include: polymorphic light eruption, cutaneous sarcoidosis, and porphyria cutanea tarda. Several randomized, controlled trials provide evidence that antimalarials are useful in suppressing disease activity in Systemic lupus erythematosus (SLE), particularly skin manifestations and fatigue. Separate studies in the UK and North America have found that continuation of hydroxychloroquine in pregnant patients with SLE is probably safe.
